Health Economics›Osteosarcoma›Relapsed refractory or metastatic first-line

Relapsed refractory or metastatic first-line

Osteosarcoma · 2 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
MAP Variant #01	—	R 11 696	21d	—	—	~4	~R 27 070 indirect	—
Cisplatin and Doxorubicin Variant #01	—	R 1 434	21d	—	—	~2	~R 2 867 PFS proxy · indirect	1

2 of 2 regimens shown